Corcept Therapeutics Statistics

Total Valuation

LON:0I3Q has a market cap or net worth of GBP 5.63 billion. The enterprise value is 5.21 billion.

Market Cap	5.63B
Enterprise Value	5.21B

Important Dates

The next estimated earnings date is Wednesday, July 30, 2025.

Earnings Date	Jul 30, 2025
Ex-Dividend Date	n/a

Share Statistics

Current Share Class	106.04M
Shares Outstanding	n/a
Shares Change (YoY)	+5.07%
Shares Change (QoQ)	+1.15%
Owned by Insiders (%)	n/a
Owned by Institutions (%)	n/a
Float	87.67M

Valuation Ratios

The trailing PE ratio is 54.90 and the forward PE ratio is 43.42.

PE Ratio	54.90
Forward PE	43.42
PS Ratio	10.61
PB Ratio	10.65
P/TBV Ratio	10.65
P/FCF Ratio	41.06
P/OCF Ratio	40.54
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

The stock's EV/EBITDA ratio is 61.81, with an EV/FCF ratio of 38.03.

EV / Earnings	50.84
EV / Sales	10.32
EV / EBITDA	61.81
EV / EBIT	64.08
EV / FCF	38.03

Financial Position

The company has a current ratio of 3.07, with a Debt / Equity ratio of 0.01.

Current Ratio	3.07
Quick Ratio	2.69
Debt / Equity	0.01
Debt / EBITDA	0.06
Debt / FCF	0.04
Interest Coverage	n/a

Financial Efficiency

Return on equity (ROE) is 21.77% and return on invested capital (ROIC) is 11.14%.

Return on Equity (ROE)	21.77%
Return on Assets (ROA)	9.18%
Return on Invested Capital (ROIC)	11.14%
Return on Capital Employed (ROCE)	15.69%
Revenue Per Employee	1.06M
Profits Per Employee	205,118
Employee Count	500
Asset Turnover	0.91
Inventory Turnover	1.04

Taxes

In the past 12 months, LON:0I3Q has paid 1.64 million in taxes.

Income Tax	1.64M
Effective Tax Rate	1.56%

Stock Price Statistics

The stock price has increased by +130.77% in the last 52 weeks.

Beta (5Y)	n/a
52-Week Price Change	+130.77%
50-Day Moving Average	72.36
200-Day Moving Average	61.31
Relative Strength Index (RSI)	49.97
Average Volume (20 Days)	453

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	8.59

Income Statement

In the last 12 months, LON:0I3Q had revenue of GBP 530.53 million and earned 102.56 million in profits. Earnings per share was 0.88.

Revenue	530.53M
Gross Profit	521.82M
Operating Income	85.42M
Pretax Income	105.35M
Net Income	102.56M
EBITDA	86.17M
EBIT	85.42M
Earnings Per Share (EPS)	0.88

Full Income Statement

Balance Sheet

The company has 249.82 million in cash and 5.29 million in debt, giving a net cash position of 436.51 million.

Cash & Cash Equivalents	249.82M
Total Debt	5.29M
Net Cash	436.51M
Net Cash Per Share	n/a
Equity (Book Value)	528.86M
Book Value Per Share	4.99
Working Capital	228.67M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was 138.88 million and capital expenditures -1.76 million, giving a free cash flow of 137.12 million.

Operating Cash Flow	138.88M
Capital Expenditures	-1.76M
Free Cash Flow	137.12M
FCF Per Share	n/a

Full Cash Flow Statement

Margins

Gross margin is 98.36%, with operating and profit margins of 16.10% and 19.55%.

Gross Margin	98.36%
Operating Margin	16.10%
Pretax Margin	19.86%
Profit Margin	19.55%
EBITDA Margin	16.24%
EBIT Margin	16.10%
FCF Margin	25.85%

Dividends & Yields

LON:0I3Q does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-5.07%
Shareholder Yield	n/a
Earnings Yield	1.82%
FCF Yield	2.44%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value
Lynch Upside
Graham Number
Graham Upside

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

LON:0I3Q has an Altman Z-Score of 19.46 and a Piotroski F-Score of 5.

Altman Z-Score	19.46
Piotroski F-Score	5